-
J. Edward Moreno
Posts
How GLP-1s elevated Hims — and brought it back down to earth
Here’s a look at how the company’s GLP-1 business has sent the stock on a wild ride Source: Sherwood News.
Novo Nordisk to slash GLP-1 list prices starting in 2027
Novo said the move will expand access for patients, “specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health…
Hims discloses SEC probe as its legal woes mount
Hims is already facing a patent infringement lawsuit from Novo Nordisk and a potential probe from the Department of Justice. Source: Sherwood News.
Hims reports Q4 earnings beat, revenue miss
The report comes as the company has faced mounting legal troubles related to its short-lived Wegovy pill copy. Source: Sherwood News.
Novo Nordisk sinks after its experimental obesity drug falls short of Eli Lilly’s in head-to-head trial
Earlier this month, Novo predicted that its sales would decline by between 5% and 13% in 2026 amid rising competition. Source: Sherwood News.
Grail tanks after cancer detection test fails in key study
Hims & Hers announced a partnership with the company earlier this month. Source: Sherwood News.
Live Nation beats Q4 revenue estimates
The company reported earnings results on Thrusday. Source: Sherwood News.
Walmart slumps after full-year guidance underwhelms
The company reported Q4 earnings results and issued its full-year outlook on Thursday. Source: Sherwood News.
DoorDash reports earnings miss, underwhelming earnings guidance
The company reported earnings results on Wednesday. Source: Sherwood News.
Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators
Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution…